Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Withdrawn Not applicable Interventional

Analysis Of Intracranial Artery Lesions Using 2-D/3D Phase Contrast MR

NCT00710281
View directory record Official record
Conditions
Intracranial Arterial Aneurysm
Interventions
Additional scan time on standard MR angiography
Radiation
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 23, 2026, 9:18 PM EDT
Enrolling by invitation No phase listed Observational

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

NCT06270719
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Delandistrogene Moxeparvovec, Standard of Care
Genetic · Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 4 Interventional

Incidence and Severity of Residual Neuromuscular Blockade

NCT02660398
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Standardized NMBD Management
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 23, 2026, 9:18 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome

NCT03779711
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Autologous (self) mononuclear cells derived from umbilical cord blood, Stage II Surgical repair
Biological · Procedure
Lead sponsor
Timothy J Nelson, MD, PhD
Other
Eligibility
Up to 12 Months
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 23, 2026, 9:18 PM EDT
Recruiting Not applicable Interventional

Partners in Control, Phase II: Using Remote Monitoring Technology With Community Health Workers to Support Hypertension Management for Latinx Patients

NCT06730230
View directory record Official record
Conditions
Hypertension
Interventions
Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Results available

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Interventions
Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
62
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CC100: Safety and Tolerability of Single Doses

NCT02050334
View directory record Official record
Conditions
Healthy
Interventions
CC100, Placebo
Drug
Lead sponsor
Chemigen, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 2 Interventional

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

NCT00542009
View directory record Official record
Conditions
Weight Management, Treatment Of Obesity
Interventions
CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD, Placebo, CE-326,597 5mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • National City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 1 Interventional

Dose-Escalation Study of GSK2126458

NCT00972686
View directory record Official record
Conditions
Solid Tumours
Interventions
GSK2126458
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
7
States / cities
San Francisco, California • New Brunswick, New Jersey • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 23, 2026, 9:18 PM EDT
Recruiting Not applicable Interventional

Using tDCS in Speech-based Stroke Rehabilitation

NCT03452202
View directory record Official record
Conditions
Apraxia of Speech
Interventions
Soterix 1x1 line tDCS low-intensity stimulator, Sham
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD

NCT01920672
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Timed Planned Activity, Home Safety and Education Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 1Phase 2 Interventional

Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant

NCT00977275
View directory record Official record
Conditions
Breast Cancer
Interventions
Interstitial Implant Brachytherapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 23, 2026, 9:18 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Adizutecan, Standard of Care, Osimertinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 9:18 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

NCT05951816
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 9:18 PM EDT
Terminated Phase 2 Interventional Results available

Dasatinib in Polycythemia Vera

NCT00538980
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Dasatinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • New City, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 23, 2026, 9:18 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Non-invasive Rejuvenation of the Periorbital Area and Lower Eyelid

NCT07028203
View directory record Official record
Conditions
Periorbital Wrinkles, Periorbital Area, Under-eyes Dark Circles, Crows Feet
Interventions
Treatment with BTL-785 with the applicator BTL-785-7-11
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Sacramento, California • Solana Beach, California • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 23, 2026, 9:18 PM EDT
Withdrawn Phase 1 Interventional

Intraperitoneal LSTA1 in CRS-HIPEC

NCT06216561
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Carcinoma, Appendix Cancer, Peritoneal Metastases
Interventions
CRS-HIPEC + LSTA1, CRS-HIPEC alone
Drug · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

NCT04662086
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Camostat
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

Crossover Trial of AD109 in Obstructive Sleep Apnea

NCT04580394
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
Drug · Diagnostic Test
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness

NCT00594022
View directory record Official record
Conditions
Insomnia, Sleeplessness, Transient Insomnia
Interventions
Electric stimulation of the Vestibular Nerve - "VirtuSom", Electric stim of the Vestibular Nerve - "VirtuSom" - SHAM
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 50 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 23, 2026, 9:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Revealing Information Genuinely & Honestly Across Time: Pediatric Oncology Stakeholder Preferences and Recommendations for Prognostic Communication

NCT05116566
View directory record Official record
Conditions
Pediatric Cancer, Communication
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 23, 2026, 9:18 PM EDT
Active, not recruiting Phase 1 Interventional

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

NCT04446351
View directory record Official record
Conditions
Neoplasms
Interventions
GSK6097608, Dostarlimab, Cobolimab, Belrestotug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Results available

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

NCT00186888
View directory record Official record
Conditions
Retinoblastoma, Retinal Neoplasm
Interventions
Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 23, 2026, 9:18 PM EDT
Completed Phase 1 Interventional

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

NCT03590054
View directory record Official record
Conditions
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Abexinostat, Pembrolizumab
Drug · Biological
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 23, 2026, 9:18 PM EDT